Approval · Notice of Compliance 7317 · 2005
DOM-SUMATRIPTAN: Notice of Compliance 7317
Issued August 24, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7317
- Date
- August 24, 2005
- Company
- Dominion PharmacalMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DOM-SUMATRIPTAN | 02270749 | Cancelled Post Market |
| DOM-SUMATRIPTAN | 02270757 | Cancelled Post Market |
| DOM-SUMATRIPTAN | 02270765 | Cancelled Post Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB